Curcumin Bioavailability: Piperine, Phytosome and Micellar — What the Head-to-Head Data Actually Show
Every curcumin supplier website has a bioavailability number: 20×, 29× and 185×. These figures come from different studies, run at different doses, measuring different things — free curcumin or conjugated metabolites — and nearly all were funded by the company that developed the formulation being tested. If you line them up and compare, you are not comparing technologies. You are comparing study designs.
The only fair comparison comes from crossover trials that gave the same subjects multiple formulations under controlled conditions. Three such studies have been published. Their conclusions contradict much of what appears on supplier websites — including the most widely cited number in the curcumin industry. This guide sets out what those studies found, explains why marketed bioavailability figures cannot be compared directly, and gives formulators a framework for choosing a delivery strategy based on evidence rather than marketing.
01 · Head-to-head data
What the Crossover Studies Actually Found
Three human crossover trials have compared multiple curcumin delivery technologies in the same subjects. Two were independent of any single ingredient supplier; one was sponsored by a formulation developer but included four competitor products alongside its own. The table below summarises what each technology achieved in each study, and whether the result reached statistical significance.
| Technology | Kocher 2021 12 adults · 8 formulations · equal dose (207 mg curcumin) · double-blind | Fança-Berthon 2021 30 adults · 5 formulations · recommended doses · open-label | Jäger 2025 9 males · 3 formulations · ~570 mg curcumin · crossover |
|---|---|---|---|
| Standard extract (95% curcuminoids) | Baseline | Baseline | Baseline |
| Piperine + curcumin | Not significant | No significant difference from standard extract | "Piperine addition provided no benefit" |
| Phospholipid complex (phytosome) | Not significant | Not significant vs standard extract | — |
| Liquid micelles | 57× (significant) | Highest AUC (136 ng·h/mL/mg dose-normalised) | Tested |
| γ-Cyclodextrin complex | 30× (significant) | — | — |
| Dried colloidal suspension | — | 72.9× dose-normalised (significant) | — |
| Nanoparticle (Theracurmin-type) | — | — | — |
| Liposomes | Not significant | — | — |
| Turmeric essential oils | Not significant | — | — |
| Submicron particles | Not significant | — | — |
Two patterns are consistent across all three studies. Micelle-based delivery ranked first in every trial that included it. And piperine failed to produce a statistically significant improvement over unformulated curcumin in every trial that tested it — a finding that directly contradicts the most widely cited figure in the curcumin industry.
Kocher 2021 went further than the others
The Hohenheim University group did not stop at pharmacokinetics. They ran parallel in-vitro experiments — simulated digestion, solubility measurement, micellisation efficiency and Caco-2 cell transport — on all eight formulations. Their conclusion reframed the entire bioavailability discussion: strategies that increase curcumin's post-digestive solubility and stability are the ones that work in vivo, whereas strategies that target post-absorptive processes — including piperine's inhibition of glucuronidation — appear ineffective.[1] Micelles achieved 100% digestive stability, 80% post-digestive solubility and 55% micellisation efficiency. No other formulation came close on all three measures.
Put differently: piperine works on a problem (rapid metabolism) that sits downstream of the real bottleneck (getting curcumin dissolved and through the gut wall). The crossover data suggest that by the time curcumin reaches the metabolic enzymes that piperine inhibits, there is almost nothing left to protect.
02 · Reading the numbers
Why the Numbers on Supplier Websites Cannot Be Compared Directly
Before evaluating any individual technology, a formulator needs to understand three things about the published bioavailability figures that appear in marketing materials. Each one, on its own, can make a meaningful comparison impossible.
Dose normalisation changes the picture
The phytosome formulation Meriva was reported to deliver 29-fold higher total curcuminoid absorption than unformulated curcumin.[2] That number is real and comes from a well-conducted crossover trial. But the trial gave subjects 209 mg of total curcuminoids from Meriva versus 1,799 mg from the unformulated mixture — a roughly eight-fold difference in curcuminoid input. Meriva contains approximately 20% curcuminoids by weight; the rest is phospholipid and microcrystalline cellulose. Professor Appendino, the lead author, acknowledged in a published response that on an equal-weight basis (500 mg of phytosome versus 500 mg of plain curcumin), the absorption increase is closer to six-fold.[3] The 29× figure describes absorption per unit of formulated product at recommended doses. The ~6× figure describes absorption per unit of curcuminoid input. Both are correct; they measure different things. Supplier marketing materials almost always cite 29×.
Free curcumin versus conjugated metabolites
Most curcumin pharmacokinetic studies treat plasma samples with glucuronidase and sulfatase enzymes before analysis, which cleaves the conjugated metabolites back into free curcumin and reports the total. But free curcumin is the form generally considered bioactive, and conjugated curcumin glucuronide and sulfate — while they retain the core chemical structure — have not been shown to produce the same biological effects at the same concentrations.[4] Cuomo 2011 explicitly stated that only phase-2 metabolites were detectable after Meriva administration — no free curcumin was found in plasma.[2] The Jäger 2025 study found that free curcumin remained below 2 nM in nearly all subjects, across all formulations tested, including those with high total AUC values.[5]
The practical consequence: a formulation that reports a 185-fold AUC increase and one that reports a 29-fold increase may have measured fundamentally different analytes. Comparing their fold-change numbers without knowing which form was measured — and whether enzymatic hydrolysis was applied — is not a meaningful comparison.
Nearly every published PK study was funded by its subject's developer
This does not mean the data are fabricated. Funded studies go through peer review and use standard pharmacokinetic methods. But it does mean that no company has a financial incentive to publish an unflattering comparison with a competitor. The table below adds the funding column that supplier websites leave out.
| Study | Key finding marketed | Funded or authored by |
|---|---|---|
| Shoba 1998[6] | 2,000% AUC increase with piperine | Sabinsa Corporation (BioPerine developer); co-authored by Sabinsa's founder |
| Cuomo 2011[2] | 29× absorption for phytosome | Indena (Meriva developer); conducted at USANA in collaboration with Indena |
| Schiborr 2014[7] | 185× AUC for liquid micelles | Frutarom / Aquanova (NovaSOL developer) |
| Sasaki 2011[8] | 27× AUC for nanoparticles | Theravalues Corporation (Theracurmin developer) |
| Fança-Berthon 2021[9] | 24× for dried colloidal suspension | Naturex / Givaudan (TurmiPure Gold developer) |
The independently funded studies — Kocher 2021 (academic, Hohenheim University)[1] and Jäger 2025 (independent crossover)[5] — are the ones that found piperine ineffective, phytosome not significantly better than standard extract, and micelles as the only consistently significant technology. Formulators drawing from the full evidence base, not just the manufacturer-funded slice, will arrive at a different shortlist than supplier websites suggest.
03 · Piperine
Piperine — What the Independent Data Show
The 2,000% figure comes from a 1998 study published in Planta Medica by Shoba and colleagues at Sabinsa Corporation.[6] Eight healthy volunteers received 2 g of curcumin alone or with 20 mg of piperine. Curcumin alone produced serum levels that were "undetectable or very low." Adding piperine increased the AUC by 2,000%. That number has driven the entire "turmeric + black pepper" category for twenty-seven years.
It has not been replicated in any subsequent study with a comparable or larger sample size. The UK Committee on Toxicity reviewed the evidence in 2022 and stated directly: "there is a lack of any further studies providing direct evidence of piperine enhancing the bioavailability of curcumin in humans."[10]
Why the later studies disagree
Fança-Berthon and colleagues, whose 30-subject crossover trial found no significant difference between piperine-curcumin and unformulated curcumin, offered three specific methodological explanations for the discrepancy with Shoba 1998[9][10]:
- Sample size. Shoba studied 8 subjects. With curcumin pharmacokinetics showing the high inter-individual variability observed in every subsequent trial, 8 subjects may be insufficient to distinguish a real effect from noise.
- Sampling window. Shoba collected blood for 6 hours. Fança-Berthon found that unenhanced curcumin reached its Tmax at approximately 6 hours — the exact point where Shoba's data collection ended. If the unenhanced curcumin in Shoba's study was still rising when sampling stopped, the "undetectable" baseline was an artefact of a truncated collection window, and the 2,000% fold-change was calculated against an artificially low denominator.
- Analytes measured. Shoba measured curcumin only. Fança-Berthon measured all three curcuminoids plus their phase-2 metabolites over 24 hours, capturing the full pharmacokinetic profile that a 6-hour, single-analyte design would miss.
Drug-interaction considerations
Piperine is a relatively selective non-competitive inhibitor of CYP3A4 (Ki = 5.4 μM), the enzyme responsible for the first-pass metabolism of a large proportion of oral drugs. In vitro, the curcuminoid-piperine combination inhibited CYP3A4 more than five-fold more potently than CYP3A5, and was predicted to inhibit CYP3A, CYP2C9, UGT and SULT metabolism within the intestinal mucosa.[11] A subsequent human study (4 g curcuminoids + 24 mg piperine over 2 days) did not find clinically significant changes in midazolam or flurbiprofen pharmacokinetics — but the authors attributed this to the short dosing period and the low plasma concentrations actually achieved.[12]
The in-vivo interaction risk remains uncertain rather than disproven. For finished-product brands whose consumers are likely to take curcumin alongside prescription medications — particularly anticoagulants, immunosuppressants or drugs with narrow therapeutic windows — piperine introduces a labelling consideration that non-piperine formulations avoid.
Why piperine is still everywhere
None of this means piperine will disappear. The compound is off-patent, costs almost nothing, requires no change to existing capsule-fill processes, and sits behind a consumer search volume that makes "turmeric and black pepper" one of the most commercially valuable phrases in the supplement industry. The 2,000% claim has been repeated so many thousands of times that it has become background knowledge for supplement consumers. For a formulator, the honest assessment is: piperine's cost and consumer recognition are genuine advantages; its pharmacokinetic evidence, when measured against independent data, is not.
04 · Delivery technologies
Micelles, Phytosomes, Nanoparticles and Cyclodextrins — Evidence and Mechanism
Kocher 2021 drew a line through the field: formulations that increase post-digestive solubility work; formulations that target metabolism do not.[1] The technologies below sit on the effective side of that line, though their evidence quality and practical constraints differ considerably.
Micelles — strongest PK data, liquid-only constraint
Polysorbate 80 micelles (NovaSOL is the branded version) ranked first in every head-to-head study that included them. The mechanism is direct: the hydrophobic micelle core dissolves curcumin, the hydrophilic shell keeps the particle dispersed in the aqueous gut, and the system protects curcumin through the entire digestive tract — Kocher 2021 measured 100% digestive stability for the micellar formulation versus less than 72% for every other format tested.[1]
An unexpected finding from Schiborr 2014 deserves more attention than it receives: women absorbed micellar curcumin 2.4 times more efficiently than men (AUC 277× in women versus 114× in men, relative to native curcumin).[7] The mechanism is unknown and the observation has not been explained or accounted for in any dosing guidance. For clinical trials and dose-finding studies, this sex difference is a confound that has so far been ignored.
The practical limitation is physical form. NovaSOL is a liquid concentrate containing approximately 6% curcuminoids. Delivering 500 mg of curcuminoids from this format would require over 8 grams of product — workable in a liquid shot or a functional beverage, impossible in a two-capsule-per-day supplement. The 185× PK figure is real, but it belongs to a delivery system that restricts the dosage form. This system also protects curcumin from degradation in near-neutral beverages — a dual benefit covered in our curcumin stability guide.
γ-Cyclodextrin complexes — solid form, independent data
The γ-cyclodextrin complex was the second technology to reach statistical significance in Kocher 2021, with a 30-fold AUC increase.[1] The mechanism is inclusion: the curcumin molecule sits inside the cyclodextrin's hydrophobic cavity, which increases water solubility and protects the compound through digestion. In the Kocher in-vitro panel, the cyclodextrin complex showed 73% digestive stability, 33% post-digestive solubility and 23% micellisation efficiency — below micelles on every measure, but far above every other formulation tested.
The practical advantage is that γ-cyclodextrin complexes are solid powders that can be filled into standard capsules and compressed into tablets. For formulators making a two-capsule-per-day product who want independent PK evidence behind their choice, this technology occupies a position that micelles and nanoparticles cannot.
Phospholipid complexes (phytosomes) — clinical history, PK questions
Meriva is the most clinically studied curcumin formulation in the world — not for pharmacokinetics, but for functional endpoints. Multiple controlled trials have reported improvements in joint comfort, inflammatory markers and other outcomes at doses of 1,000 mg Meriva per day (delivering roughly 200 mg of curcuminoids).[2] These functional results are genuine, and they are the reason Meriva dominates the premium supplement segment.
The pharmacokinetic picture is less clear. The 29× total curcuminoid absorption figure is valid at the doses tested, but it translates to approximately 6× on a per-curcuminoid-input basis because Meriva is only ~20% curcuminoids. In both Kocher 2021 and Fança-Berthon 2021, the phytosome did not reach statistical significance for AUC improvement over unformulated curcumin.[1][9] And the Cuomo 2011 study detected only conjugated metabolites in plasma — no free curcumin.[2]
One way to reconcile these findings: Meriva's clinical efficacy may not depend on high systemic plasma curcumin levels. The phospholipid complex may produce its effects through improved intestinal permeability, local gut activity, or changes in the curcuminoid profile — Cuomo 2011 noted that DMC absorption was enhanced much more than curcumin I, making DMC the dominant plasma curcuminoid after Meriva, and DMC is more potent than curcumin I in several in-vitro anti-inflammatory assays.[2]
Nanoparticles (Theracurmin) — limited independent verification
Theracurmin reported a 27-fold AUC increase in a 2011 study with six healthy volunteers.[8] The formulation is a colloidal nanoparticle dispersion containing about 10% curcumin by weight. It has not appeared in any of the three published independent head-to-head crossover studies. Its clinical development has focused on oncology (dose-escalation PK) and knee osteoarthritis rather than on PK comparisons with other delivery systems. Without independent crossover data, its position relative to micelles or cyclodextrin complexes remains a manufacturer's claim rather than a verified comparison.
05 · Decision framework
How to Choose a Delivery Strategy
Bioavailability data narrows the shortlist. But a formulator also needs to know what physically fits in a capsule, what the technology costs, and whether high plasma AUC actually predicts the clinical outcome the product is targeting. The tables below put those factors side by side.
What physically fits in a capsule
A standard two-piece capsule (size 00) holds approximately 735 mg of powder. The table shows what each delivery technology requires to reach 200 mg of curcuminoids — a dose in the range used in the phytosome clinical trials and roughly equivalent to 1,000 mg of raw turmeric spice.
| Technology | Curcuminoid content | Weight needed for 200 mg curcuminoids | Capsules (size 00) |
|---|---|---|---|
| Standard 95% extract | ~95% | ~211 mg | 1 capsule, with room to spare |
| γ-Cyclodextrin complex | Variable (typically 15–30%) | ~670–1,330 mg | 1–2 capsules |
| Phospholipid complex (Meriva-type) | ~20% | ~1,000 mg | 2 capsules |
| Nanoparticle dispersion (Theracurmin-type) | ~10% | ~2,000 mg | 3 capsules (or liquid format) |
| Liquid micelles (NovaSOL-type) | ~6% | ~3,330 mg | Not feasible in capsules; liquid shot or beverage only |
This is the constraint that PK charts do not show. The technology with the strongest pharmacokinetic data (micelles, 57–185×) cannot be put into a standard capsule at a meaningful curcuminoid dose. The technology with the second-strongest independent data (γ-cyclodextrin, 30×) can. And an unenhanced 95% extract fits a full clinical dose into a single capsule — the simplest possible supplement format.
Cost, evidence and dosage form — choosing by priority
| Your priority | Direction | Cost tier | Evidence basis |
|---|---|---|---|
| Highest AUC per mg curcuminoid | Micelle system (liquid format) | $$$ | Ranked first in every head-to-head crossover trial |
| Solid capsule or tablet with independent PK data | γ-Cyclodextrin complex | $$ | 30× in Kocher 2021 (significant); no industry-funded study required |
| Extensive clinical trial history on functional endpoints | Phospholipid complex (phytosome) | $$–$$$ | Multiple positive RCTs on joint comfort; PK advantage modest on a per-curcuminoid basis |
| Consumer expects "turmeric + pepper" | Piperine | $ | Strong consumer recognition; PK claim not supported by independent crossover data |
| Lowest ingredient cost, simplest formulation | Standard 95% extract + fatty-meal instruction | $ | Fat co-ingestion improves solubility; no branded cost premium |
| Liquid beverage or RTD format | Micelle system | $$$ | Water-dispersible; simultaneously addresses stability and absorption |
| Avoid drug-interaction labelling risk | Any non-piperine option | Varies | Eliminates the CYP3A4 inhibition consideration entirely |
One further variable that the table above does not capture: market-specific regulatory status. In the EU, curcumin used as a dietary supplement ingredient — as opposed to the food colourant E 100 — is classified as a Novel Food, requiring separate authorisation. The delivery technology you choose does not change that classification, and it applies regardless of whether the curcumin is enhanced or unformulated. Our guide to curcumin in the EU: food colour E 100 vs supplement Novel Food covers the distinction in detail.
Bioavailability does not predict clinical efficacy
One pattern in the literature complicates the entire discussion: the technology with the weakest independent PK data (phytosome) has the strongest published clinical outcomes, while the technology with the strongest PK data (micelles) has relatively few published clinical trials on functional endpoints. A 2017 review asked the question directly — why does a significant increase in curcumin bioavailability not correspond to a bioactivity increase of equal magnitude?[13]
Several explanations have been proposed: curcumin may act locally in the gut rather than systemically, its conjugated metabolites may retain some activity, and tissue-level concentrations may not correlate with plasma AUC. Whatever the mechanism, the implication for formulators is that pharmacokinetic data should narrow your options, not make the final decision. The final decision rests on pilot-batch work and, where possible, a clinical study in the population your product is intended for.
PhytoVale supplies turmeric root extract in three curcuminoid grades — 50%, 95% and 98% by HPLC — with or without maltodextrin carrier. We do not sell branded bioavailability-enhancement technologies. The delivery strategy is a downstream formulation decision. We can advise on which curcuminoid grade and carrier option best suits your chosen delivery system — contact us with your formulation brief.
06 · Evidence base
References
[1] Kocher A, Schiborr C, Behnam D, Frank J. Increasing post-digestive solubility of curcumin is the most successful strategy to improve its oral bioavailability: a randomized cross-over trial in healthy adults and in vitro bioaccessibility experiments. Molecular Nutrition & Food Research. 2021;65(24):2100613. DOI
[2] Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. Journal of Natural Products. 2011;74(4):664–669. DOI
[3] Appendino G. Response to "fuzzy math" claim regarding Meriva curcumin phytosome absorption data. NutraIngredients, April 2011. On an equal-weight basis (500 mg phytosome versus 500 mg plain curcumin), the absorption increase is approximately six-fold.
[4] Mahale J, Singh R, Howells LM, Griffiths TRL, Brown K. The fallacy of enzymatic hydrolysis for the determination of bioactive curcumin in plasma samples as an indication of bioavailability: a comparative study. BMC Complementary Medicine and Therapies. 2019;19:293. DOI
[5] Jäger R, et al. A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience. 2025;28:112575. DOI
[6] Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64(4):353–356. DOI
[7] Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Molecular Nutrition & Food Research. 2014;58(3):516–527. DOI
[8] Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biological and Pharmaceutical Bulletin. 2011;34(5):660–665. DOI
[9] Fança-Berthon P, Tenon M, Le Bouter-Banon S, et al. Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. Journal of Nutrition. 2021;151(7):1802–1816. DOI
[10] UK Committee on Toxicity (COT). Statement on the potential risk to human health of turmeric and curcumin supplements. 2022. COT
[11] Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metabolism and Disposition. 2008;36(8):1594–1605. DOI
[12] Volak LP, Hanley MJ, Massa G, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology. 2013;75(2):450–462. DOI
[13] Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutrition Journal. 2014;13:11; and Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Research and Treatment. 2014;46(1):2–18. DOI
Reviewed by
Prof. Bingji MaScientific Adviser, PhytoVale · Professor & Medicinal Plant Science Expert. Research focus: Chinese medicinal materials, phytochemistry, natural products and medicinal plant quality.
Written by
FloraContent Editor, PhytoVale · Product Content & Editorial Specialist. Focuses on botanical ingredient specifications, sourcing information and B2B technical content.
07 · Questions
Frequently Asked Questions
Is the 2,000% bioavailability increase from piperine real?
It was reported in a 1998 study with 8 subjects, funded by the piperine developer. Three subsequent independent crossover studies with 9 to 30 subjects each — including the largest head-to-head comparison published to date — found no statistically significant improvement in curcumin absorption from piperine co-administration. The UK Committee on Toxicity noted in 2022 that no further studies have provided direct evidence supporting the finding. The 2,000% figure is a real data point from one small study, but it has not been independently confirmed.
Which curcumin delivery technology has the best bioavailability?
Based on the published head-to-head crossover data, liquid micellar curcumin has consistently produced the highest plasma AUC — 57-fold in the equal-dose Kocher 2021 study and the highest absolute AUC in Fança-Berthon 2021. γ-Cyclodextrin complexes ranked second (30-fold). However, "best bioavailability" depends on what you measure: most studies report total curcuminoids (free plus conjugated metabolites after enzymatic hydrolysis), and whether conjugated metabolites have equivalent biological activity to free curcumin is an open question.
What does "29× better absorption" mean for the curcumin phytosome?
The Cuomo 2011 study found that Meriva (the branded phytosome) delivered 29-fold higher total curcuminoid absorption than unformulated curcumin at their respective recommended doses. Meriva contains approximately 20% curcuminoids; the rest is phospholipid and cellulose. On a per-curcuminoid-input basis, the improvement is closer to 6-fold. Both figures are correct — they describe different things. In the two subsequent independent crossover studies (Kocher 2021 and Fança-Berthon 2021), the phytosome did not reach statistical significance for AUC improvement over standard extract.
Do curcumin bioavailability studies measure free curcumin or conjugated metabolites?
Most measure total curcumin after treating plasma with glucuronidase and sulfatase enzymes, which converts conjugated metabolites back into free curcumin before analysis. This means the reported AUC includes both active free curcumin and its conjugated forms, which are less bioactive. A 2019 study called this "the fallacy of enzymatic hydrolysis" and argued that it obscures the amount of genuinely bioactive curcumin in the blood. A 2025 independent study found that free curcumin remained below 2 nM in nearly all subjects across all formulations, including those with high total AUC.
Does piperine cause drug interactions?
In-vitro data show that piperine is a selective CYP3A4 inhibitor (Ki = 5.4 μM), and the curcuminoid-piperine combination is predicted to inhibit CYP3A, CYP2C9, UGT and SULT enzymes at intestinal-mucosa concentrations. A short-term human study (2 days) did not find clinically significant changes in probe-drug pharmacokinetics, but the authors attributed this to the brief treatment period. Long-term interaction data are lacking. For products taken alongside CYP3A4-metabolised medications, this remains an open labelling consideration.
Can I just take curcumin with a fatty meal instead of using a delivery technology?
Fat co-ingestion does improve curcumin's dissolution in the gut, and the traditional culinary use of turmeric in oil-based dishes is consistent with this. However, the absorption improvement from dietary fat has not been quantified in a pharmacokinetic study comparable to the crossover trials discussed here, so there is no published fold-change number to compare against. For a supplement product, instructing consumers to take curcumin with food or a fatty meal is a reasonable, zero-cost strategy that avoids branded-ingredient costs — but it does not replace a delivery technology if the product's claim or positioning depends on demonstrated high bioavailability.
Does PhytoVale sell bioavailability-enhanced curcumin?
No. PhytoVale supplies turmeric root extract as a raw material in three curcuminoid grades — 50%, 95% and 98% by HPLC. Bioavailability enhancement is a downstream formulation step. We can advise on which curcuminoid grade and carrier option (with or without maltodextrin) best suits the delivery system your formulator has selected.
B2B supply
Need the Curcumin Raw Material?
PhytoVale supplies turmeric root extract in three grades — 50%, 95% and 98% curcuminoids by HPLC. Tell us your target specification, delivery system and volume, and we reply within 24 hours with a quotation and a free sample.
Request a quotation →See turmeric extract grades →Disclaimer: this article is intended for ingredient evaluation, formulation and B2B purchasing. PhytoVale supplies turmeric root extract as a raw material and makes no health claims for it. Bioavailability data are summarised from published pharmacokinetic studies as technical background for formulators, not as claim substantiation. Branded ingredient names (Meriva, NovaSOL, Theracurmin, BioPerine, TurmiPure Gold) are trademarks of their respective owners and are cited here for identification only. These statements have not been evaluated by the U.S. Food and Drug Administration, and this ingredient is not intended to diagnose, treat, cure or prevent any disease. © 2026 PhytoVale.
